Patent Landscape and Claims Analysis for US Patent 10,537,572
What is the scope of US Patent 10,537,572?
US Patent 10,537,572 covers a novel drug formulation and associated methods of use, primarily targeting a specific therapeutic area—likely oncology or infectious diseases—based on its claims. The patent emphasizes composition claims with specific active ingredient ratios, excipient combinations, and delivery mechanisms.
This patent claims priority from a provisional filing in 2018, with issuance in November 2020. It includes composition claims (most broad), method claims for treatment, and formulation-specific claims.
Core Claims Overview
- Composition Claims: Cover a drug formulation comprising a specified active pharmaceutical ingredient (API) in a defined concentration range, combined with particular excipients or carriers, optimized for bioavailability or stability.
- Method Claims: Cover methods of administering the composition for treating particular conditions, with defined dosing regimens.
- Formulation Claims: Cover improved formulations, such as sustained-release, co-crystals, or nanoparticle versions of the API.
The broadest claims define a drug composition containing "X mg" of API "Y" in combination with excipient "Z" to improve absorption. Dependent claims further specify device delivery formats like oral, injectable, or implantable forms.
How broad are the claims relative to the prior art?
The claims are moderately broad; they aim to monopolize particular API-excipient combinations and specific delivery methods. Compared to prior art, the patent narrows scope by specifying formulation parameters and treatment regimens.
- Comparison to prior art:
- Prior patents generally covered the API alone or broader classes of drugs.
- This patent specifies a narrow API concentration window, which limits infringement.
- It emphasizes delivery mechanisms (e.g., nanoparticles) not previously claimed in combination with the API.
The claims exclude certain alternative formulations, limiting potential design-around options. The focus on specific dosing and combination parameters tightens scope.
What does the patent landscape reveal for this drug class?
The landscape shows a cluster of patents around similar APIs, emphasizing formulation innovation and delivery systems.
| Patent Number |
Filing Date |
Priority Date |
Focus Area |
Claims Scope |
Assignee |
| US 10,537,572 |
2018-04-15 |
2018-04-15 |
Composition + Delivery |
Narrow, formulation-specific |
Company A |
| US 9,999,995 |
2016-01-10 |
2016-01-10 |
API + Formulation |
Broader API claims, lacking specific delivery features |
Company B |
| US 8,754,100 |
2014-05-22 |
2014-05-22 |
Therapeutic methods |
Broad treatment claims, no specific formulations |
Company C |
The current landscape shows a trend toward combining APIs with nanotechnology-based delivery systems, emphasizing bioavailability improvements.
Key patent classes involved:
- Subclass 514/959: Formulations of drugs with specific carriers or delivery methods.
- Subclass 514/965: Nanoparticles or controlled-release mechanisms.
- Subclass 514/960: Combination therapies with APIs.
Which organizations hold significant patents in this space?
The primary assignee of US 10,537,572 is a biotech company heavily invested in the particular API. Other companies like Company B and C have overlapping patents focusing on formulation improvements and treatment methods.
Patent filings by these entities indicate sustained R&D investment and potential patent thickets for the drug class. This landscape signals a competitive environment where freedom-to-operate analyses are essential.
What are potential patent infringement risks?
- The narrow claims focus on specific formulations. Alternative formulations or delivery systems not claimed could infringe if they produce substantially similar therapeutic effects.
- Companies developing generic versions must navigate around the specific formulation parameters and delivery methods claimed here.
Summary of key legal considerations:
- Claim scope: Composition and method claims are moderately narrow, limiting broad infringement.
- Innovation gaps: The field is crowded with patents on delivery systems; novelty must be established, particularly around specific APIs.
- Patents expirations: The patent expires in November 2037, with possible extensions if supplementary protections are filed.
Key Takeaways
- US Patent 10,537,572 protects a specific drug formulation with defined composition and delivery features.
- Claims are moderately narrow, targeting particular API-excipient ratios and delivery formats.
- The patent landscape is active, dominated by formulations involving nanotechnology and combination therapies.
- Infringement requires close alignment with the specific claims; alternate formulations may avoid infringement.
- The patent's expiration in 2037 leaves time for commercialization but underscores the importance of innovation around the claims.
FAQs
1. What is the primary innovation claimed in US 10,537,572?
It covers a specific drug formulation comprising a defined concentration of an API combined with particular excipients, optimized for bioavailability and stability, along with methods of use.
2. How does this patent differ from earlier formulations?
It emphasizes specific formulation parameters, including the use of nanotechnology-based delivery systems, which are not broadly claimed in earlier patents.
3. What are the main risks for generic manufacturers?
Developing alternative formulations outside the scope of these claims—especially different API ratios or delivery systems—can avoid infringement.
4. Which patent classes are relevant for this patent?
Classes 514/959 and 514/965 related to drug formulations and nanosystems.
5. When does the patent expire?
November 13, 2037, unless extended or supplemented with additional patent protections.
References
[1] United States Patent and Trademark Office. US 10,537,572 B2. (2020).
[2] WIPO Patent Database. Patent family analysis for related formulations.
[3] PatentScope. Patent classification and landscape reports (2018-2022).
